BELEODAQ. Prior Authorization Criteria Memorial Hermann HMO Formulary ID: Version 19 Effective Date: 10/27/2015. PRODUCT(s) AFFECTED BELEODAQ

Size: px
Start display at page:

Download "BELEODAQ. Prior Authorization Criteria Memorial Hermann HMO Formulary ID: Version 19 Effective Date: 10/27/2015. PRODUCT(s) AFFECTED BELEODAQ"

Transcription

1 BELEODAQ BELEODAQ All FDA approved indications not otherwise excluded from Part D. Plan Year PAGE 1

2 BEXAROTENE BEXAROTENE All Medically Accepted Indications not otherwise excluded from Part D Patient must have tried one systemic therapy Prescriber is an oncologist 12/31/2015 PAGE 2

3 BOSULIF BOSULIF Signed statement of diagnosis from the physician, hepatic panel and CBC, trial and failure ofofimiatinib or dasatinibi and documentation of a 90 day response 12/31/15 PAGE 3

4 CIALIS - CIALIS TAB 2.5 MG - CIALIS TAB 5 MG Supporting statement of diagnosis from the physician and prior trial and failure of at least one alpha blocker and one alpha reductase inhibitor 12/31/15 PAGE 4

5 DELESTROGEN DELESTROGEN OIL 10 MG/ML All FDA approved indications not otherwise excluded from Part D diagnosis of menopause and must have documented trial/failure, contraindication or intolerance to formulary generic estrogen oral product 12/31/2015 PAGE 5

6 ENTRESTO ENTRESTO 1. Must have diagnosis of CHF (II-IV) AND 2. Must have concurrent therapy with BB AND 3. EF less than or equal 40% AND 4. No documented case of angiodema from prior ACEI/ARB therapy Must be prescribed by cardiologist 12/31/2015 PAGE 6

7 ERWINAZE ERWINAZE Supporting statement of diagnosis from the physician 12/31/15 PAGE 7

8 ESBRIET ESBRIET Appropriate diagnosis (idopathic pulmonary fibrosis [IPF]) and monitoring (hepatiac function/lfts) Prescriber must be a pulmonologist 12/31/2015 PAGE 8

9 ESRD THERAPY PROCRIT Hemogloblin less than 10 g/dl for patients receiving Cancer Chemotherapy and Hemoglobin less than 12 and Hematacrit less than 33 for other approved FDA indications in addition to supporting statement of diagnosis from physician 3 months PAGE 9

10 FARYDAK FARYDAK Statement of diagnosis from physician 12/31/2015 PAGE 10

11 FENTANYL - FENTORA TAB 200 MCG - FENTORA TAB 600 MCG - FENTORA TAB 400 MCG - FENTORA TAB 800 MCG - LAZANDA Supporting statement of diagnosis from the physician 12/31/15 PAGE 11

12 FULYZAQ FULYZAQ All FDA approved indications not otherwise excluded from Part D. Dx of non-infectious diarrhea and HIV, member must be on antiretroviral therapy. 12/31/15 PAGE 12

13 GILOTRIF GILOTRIF Supporting statement of diagnosis from the physician in patients with EGFR exon 19 deletions or exon 21 (L858R) substitution as detected by an FDA-approved test. 12/31/15 PAGE 13

14 GROWTH HORMONE - HUMATROPE RECON SOLN 12 MG - - NUTROPIN AQ NUSPIN NUTROPIN AQ PEN SOLUTION 20 MG/2ML - HUMATROPE RECON SOLN 24 MG NUTROPIN AQ NUSPIN 5 SAIZEN - SAIZEN CLICK.EASY Supporting statement of diagnosis from the physician 12/31/15 PAGE 14

15 HARVONI HARVONI Must submit documentation of chronic hepatitis C genotype (confirmed by HCV RNA level within the last 6 months) and subtype. Must submit laboratory results within 6 weeks of initiating therapy including: 1) CBC w Platelets, 2) AST/ALT, 3)Total Bilirubin, 4)Serum Albumin, 5)PT/INR, 6)Serum Creatinine, and 7)GFR. Patient must be age 18 or over Prescriber must be a gastroenterologist, hepatologist, or infectious disease specialist 24 weeks: treatment-experienced with cirrhosis, 12 weeks: All others PAGE 15

16 HRM - AMITRIPTYLINE HCL TAB 10 MG - - AMITRIPTYLINE HCL TAB 150 MG - - AMITRIPTYLINE HCL TAB 50 MG - - ASCOMP-CODEINE - - BENZTROPINE MESYLATE TAB 1 MG - - BUTALBITAL-APAP-CAFF-COD CAP MG - CHLORDIAZEPOXIDE-AMITRIPTYLINE - - CLOMIPRAMINE HCL CAP 25 MG - - CLOMIPRAMINE HCL CAP 75 MG - - CYCLOBENZAPRINE HCL TAB 5 MG - - CYPROHEPTADINE HCL TAB 4 MG - - DIGOX TAB 250 MCG - - DIGOXIN SOLUTION 0.25 MG/ML - - DIPYRIDAMOLE TAB 25 MG - - DIPYRIDAMOLE TAB 75 MG - - DISOPYRAMIDE PHOSPHATE CAP 150 MG - - DOXEPIN HCL CAP 100 MG - - DOXEPIN HCL CAP 25 MG - - DOXEPIN HCL CAP 75 MG - - ESTRADIOL TAB 0.5 MG - - ESTRADIOL TAB 2 MG - - GLYBURIDE 2.5 MG - - GLYBURIDE TAB 1.25 MG - AMITRIPTYLINE HCL TAB 100 MG AMITRIPTYLINE HCL TAB 25 MG AMITRIPTYLINE HCL TAB 75 MG BENZTROPINE MESYLATE TAB 0.5 MG BENZTROPINE MESYLATE TAB 2 MG BUTISOL SODIUM TAB 30 MG CHLORPROPAMIDE CLOMIPRAMINE HCL CAP 50 MG CYCLOBENZAPRINE HCL TAB 10 MG CYPROHEPTADINE HCL 4 MG DIGITEK TAB 250 MCG DIGOXIN SOLUTION 0.05 MG/ML DIGOXIN TAB 250 MCG DIPYRIDAMOLE TAB 50 MG DISOPYRAMIDE PHOSPHATE CAP 100 MG DOXEPIN HCL CAP 10 MG DOXEPIN HCL CAP 150 MG DOXEPIN HCL CAP 50 MG DOXEPIN HCL CONC 10 MG/ML ESTRADIOL TAB 1 MG GLYBURIDE 1.25 MG GLYBURIDE MICRONIZED GLYBURIDE TAB 2.5 MG GLYBURIDE-METFORMIN - GLYBURIDE TAB 5 MG - PAGE 16

17 - GUANFACINE HCL ER - - HYDROXYZINE HCL 25 MG - - HYDROXYZINE HCL SOLUTION 10 MG/5ML - - HYDROXYZINE HCL TAB 10 MG - - HYDROXYZINE HCL TAB 50 MG - - HYDROXYZINE PAMOATE CAP 25 MG - - IMIPRAMINE HCL TAB 10 MG - - IMIPRAMINE HCL TAB 50 MG - - INDOMETHACIN CAP 25 MG - - INDOMETHACIN ER - - KETOROLAC TROMETHAMINE 30 MG/ML - - KETOROLAC TROMETHAMINE SOLUTION - 15 MG/ML - KETOROLAC TROMETHAMINE SOLUTION - 60 MG/2ML - MACRODANTIN CAP 50 MG - - MEGESTROL ACETATE SUSPENSION 40 - MG/ML - MEGESTROL ACETATE TAB 20 MG - - MENEST - - METHOCARBAMOL TAB 500 MG - - METHYLDOPA TAB 250 MG - - METHYLDOPA-HYDROCHLOROTHIAZIDE - - METHYLPHENIDATE HCL ER TAB ER 24H - 27 MG - NIFEDIPINE CAP 10 MG - - NITROFURANTOIN MACROCRYSTAL CAP MG - NITROFURANTOIN MONOHYD MACRO - HYDROXYZINE HCL 10 MG HYDROXYZINE HCL 50 MG HYDROXYZINE HCL SYRUP 10 MG/5ML HYDROXYZINE HCL TAB 25 MG HYDROXYZINE PAMOATE CAP 100 MG HYDROXYZINE PAMOATE CAP 50 MG IMIPRAMINE HCL TAB 25 MG IMIPRAMINE PAMOATE INDOMETHACIN CAP 50 MG KETOROLAC TROMETHAMINE 15 MG/ML KETOROLAC TROMETHAMINE 60 MG/2ML KETOROLAC TROMETHAMINE SOLUTION 30 MG/ML KETOROLAC TROMETHAMINE TAB 10 MG MEGACE ES MEGESTROL ACETATE SUSPENSION 400 MG/10ML MEGESTROL ACETATE TAB 40 MG MEPROBAMATE METHOCARBAMOL TAB 750 MG METHYLDOPA TAB 500 MG METHYLDOPATE HCL METHYLPHENIDATE HCL ER TAB ER 27 MG NIFEDIPINE CAP 20 MG NITROFURANTOIN MACROCRYSTAL CAP 50 MG ORPHENADRINE CITRATE ER PAGE 17

18 - ORPHENADRINE CITRATE SOLUTION 30 MG/ML - PERPHENAZINE-AMITRIPTYLINE - PREMARIN TAB 0.45 MG - PREMARIN TAB 0.9 MG - PREMPHASE - RESERPINE TAB 0.1 MG - SURMONTIL - THIORIDAZINE HCL TAB 100 MG - THIORIDAZINE HCL TAB 50 MG - TRIHEXYPHENIDYL HCL - PENTAZOCINE-NALOXONE HCL - PREMARIN TAB 0.3 MG - PREMARIN TAB MG - PREMARIN TAB 1.25 MG - PREMPRO - SECONAL - THIORIDAZINE HCL TAB 10 MG - THIORIDAZINE HCL TAB 25 MG - TICLOPIDINE HCL - ZALEPLON 10 MG - ZALEPLON CAP 10 MG - ZOLPIDEM TARTRATE High risk medication. Automatically approved for beneficiaries less than or equal to 64 years. Attestation to the medical necessity for using this high risk medication, AND Monitoring plan for adverse side effects, AND Anticipated treatment course/duration, AND If formulary alternatives considered safe and effective in the elderly are available, then the member had an inadequate response, intolerable side effect, or contraindication to the alternative(s). Less than or equal to 64 years old, claim for target drug automatically pays. Greater than or equal to 65 years old, prior authorization exception request is required indicating medically accepted indication not otherwise excluded from Part D. PAGE 18

19 12/31/15 PAGE 19

20 HRM2 MEGESTROL ACETATE SUSPENSION 625 MG/5ML High risk medication. Automatically approved for beneficiaries less than or equal to 64 years. Attestation to the medical necessity for using this high risk medication, AND Monitoring plan for adverse side effects, AND Anticipated treatment course/duration, AND If formulary alternatives considered safe and effective in the elderly are available, then the member had an inadequate response, intolerable side effect, or contraindication to the alternative(s). Less than or equal to 64 years old, claim for target drug automatically pays. Greater than or equal to 65 years old, prior authorization exception request is required indicating medically accepted indication not otherwise excluded from Part D. NONE 12/31/2015 PAGE 20

21 IBRANCE IBRANCE All FDA approved indications not otherwise excluded from part D Appropriate diagnosis (used in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced breast cancer) 12/31/2015 PAGE 21

22 ICLUSIG ICLUSIG Must have documented trial and failure of another tyrosine kinase inhibitor Plan Year PAGE 22

23 IMBRUVICA IMBRUVICA Supporting statement of diagnosis from the physician 12/31/15 PAGE 23

24 KALYDECO KALYDECO Supporting statement of diagnosis from the physician 12/31/15 PAGE 24

25 KEYTRUDA KEYTRUDA Must have documented trial and failure or contraindication to Yervoy. If patient is BRAF V600 mutation positive, must also try a BRAF inhibitor prior to approval of Keytruda Plan Year PAGE 25

26 KORLYM KORLYM Pregnancy Supporting statement of diagnosis and relevant medical information from physician 12/31/15 PAGE 26

27 LIDODERM LIDODERM 12/31/15 PAGE 27

28 LYNPARZA LYNPARZA Appropriate diagnosis and testing for BRCA mutation (deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA approved test) advanced ovarian cancer that has been treated with 3 or more prior lines of chemotherapy) none none 12/31/2015 none PAGE 28

29 NORTHERA NORTHERA Prior authorization will be approved for the following indication(s): orthostatic dizziness, lightheadedness, or "the feeling that you are about to black out" in adults with neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (i.e., Parkinson disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy) Plan Year PAGE 29

30 OLYSIO OLYSIO Must have chronic hepatitis C genotype 1 infection. Must not have Q80K polymorphism resistance (confirmed by Genosure NS3/4 resistance testing). Patient must be age 18 or over Prescriber must be a gastroenterologist, hepatologist, or infectious disease specialist 12 weeks PAGE 30

31 OPDIVO OPDIVO Appropriate diagnosis (unresectable or metastatic melanoma and disease progression following ipilimumab [Yervoy]) and testing for BRAF V600 mutation. none none 12/31/2015 none PAGE 31

32 ORENITRAM ORENITRAM All FDA approved indications not otherwise excluded from Part D. Supporting statement of diagnosis from the physician 12/31/15 PAGE 32

33 ORKAMBI ORKAMBI "Initial Therapy: Must have 1. diagnosis of cystic fibrosis (CF) with documented homozygous F508del mutation confirmed by FDA-approved CF mutation test AND 2. Baseline FEV1 greater than or equal to 40% AND 3. Baseline liver function tests (ALT/AST and bilirubin) provided AND 4. If less than 18 years of age, baseline ophthalmological exam completed Continuation of therapy: 1. Documentation patient is tolerating and responding to medication (i.e. improved FEV1, weight gain, decreased exacerbations, etc.) AND 2. Adherence to therapy is confirmed (supported by documentation from patient s chart notes or electronic claim history) AND 3. Liver function tests (ALT/AST and bilirubin) provided with each renewal during first year of treatment and annually thereafter AND 4. ALT or AST does not exceed 5 times the upper limit of normal AND 5. ALT or AST does not exceed 3 times upper limit of normal with bilirubin greater than 2 times upper limit of normal" Must be greater than or equal to 12 years of age Must be prescribed by, or in conjunction with, a pulmonologist or is from a CF center accredited by PAGE 33

34 the Cystic Fibrosis Foundation 12/31/2015 PAGE 34

35 PART D VS PART B - ABRAXANE - ALBUTEROL SULFATE NEBU SOLN (2.5 MG/3ML) 0.083% - ALBUTEROL SULFATE NEBU SOLN 0.63 MG/3ML - AMBISOME - AMINOSYN II SOLUTION 7 % - AMINOSYN II/ELECTROLYTES - AMINOSYN-HBC - AMINOSYN-RF - ARRANON - ASTAGRAF XL - AZATHIOPRINE TAB 50 MG - BICNU - BUDESONIDE SUSPENSION 1 MG/2ML - CARBOPLATIN SOLUTION 150 MG/15ML - CARBOPLATIN SOLUTION 50 MG/5ML - CISPLATIN SOLUTION 100 MG/100ML - CALCITONIN (SALMON) - CELLCEPT INTRAVENOUS - CHLORPROMAZINE HCL SOLUTION 50 MG/2ML - CLADRIBINE - CLINIMIX E/DEXTROSE (2.75/5) - CLINIMIX E/DEXTROSE (4.25/25) - ADRUCIL - ALBUTEROL SULFATE NEBU SOLN (5 MG/ML) 0.5% - ALBUTEROL SULFATE NEBU SOLN 1.25 MG/3ML - AMINOSYN II SOLUTION 10 % - AMINOSYN II SOLUTION 8.5 % - AMINOSYN M - AMINOSYN-PF - AMINOSYN/ELECTROLYTES - ARZERRA - ATGAM - AZASAN - BIVIGAM - BUSULFEX - CARBOPLATIN SOLUTION 450 MG/45ML - CARBOPLATIN SOLUTION 600 MG/60ML - CISPLATIN SOLUTION 50 MG/50ML - CARIMUNE NF - CHLORPROMAZINE HCL SOLUTION 25 MG/ML - CHLORPROMAZINE HCL TAB 10 MG - CLINIMIX E/DEXTROSE (2.75/10) - CLINIMIX E/DEXTROSE (4.25/10) - CLINIMIX E/DEXTROSE (4.25/5) PAGE 35

36 - CLINIMIX E/DEXTROSE (5/15) - - CLINIMIX E/DEXTROSE (5/25) - - CLINIMIX/DEXTROSE (4.25/10) - - CLINIMIX/DEXTROSE (4.25/25) - - CLINIMIX/DEXTROSE (5/15) - - CLINIMIX/DEXTROSE (5/25) - - COSMEGEN - - CYCLOSPORINE 100 MG - - CYCLOSPORINE CAP 25 MG - - CYCLOSPORINE SOLUTION 50 MG/ML - - CYCLOPHOSPHAMIDE CAP 50 MG - - CYTARABINE (PF) - - DAUNORUBICIN HCL - - DACARBAZINE RECON SOLN 200 MG - - DEPO-PROVERA SUSPENSION 400 MG/ML - - DEXAMETHASONE SODIUM PHOSPHATE - SOLUTION 10 MG/ML - DOXIL - - ELLENCE - - EMEND CAP 40 MG - - EMEND CAP 80 MG - - EPIRUBICIN HCL SOLUTION 200 MG/100ML - - ETOPOPHOS - - ETOPOSIDE SOLUTION 100 MG/5ML - - FLEBOGAMMA DIF SOLUTION 10 - GM/100ML - FLEBOGAMMA DIF SOLUTION 5 GM/50ML - - FLUOROURACIL SOLUTION 2.5 GM/50ML - CLINIMIX E/DEXTROSE (5/20) CLINIMIX/DEXTROSE (2.75/5) CLINIMIX/DEXTROSE (4.25/20) CLINIMIX/DEXTROSE (4.25/5) CLINIMIX/DEXTROSE (5/20) CLOLAR CROMOLYN SODIUM NEBU SOLN 20 MG/2ML CYCLOSPORINE CAP 100 MG CYCLOSPORINE MODIFIED CYCLOPHOSPHAMIDE CAP 25 MG CYRAMZA CYTARABINE SOLUTION 20 MG/ML DOXORUBICIN HCL DAUNOXOME DEXAMETHASONE SOD PHOSPHATE PF DOCEFREZ RECON SOLN 20 MG ELIGARD EMEND CAP 125 MG EMEND CAP 80 & 125 MG ENGERIX-B EPIRUBICIN HCL SOLUTION 50 MG/25ML ETOPOSIDE SOLUTION 1 GM/50ML ETOPOSIDE SOLUTION 500 MG/25ML FLEBOGAMMA DIF SOLUTION 20 GM/200ML FLUOROURACIL SOLUTION 1 GM/20ML FLUOROURACIL SOLUTION 5 GM/100ML PAGE 36

37 - FLUOROURACIL SOLUTION 500 MG/10ML - - FREAMINE HBC - - GAMMAGARD S/D - - GAMMAKED - - GANCICLOVIR SODIUM - - GRANISETRON HCL - - HERCEPTIN - - IDAMYCIN PFS - - IFOSFAMIDE - - IPRATROPIUM BROMIDE SOLUTION 0.02 % - - IRINOTECAN HCL SOLUTION 100 MG/5ML - - IXEMPRA KIT - - KEPIVANCE - - MELPHALAN HCL - - METHOTREXATE SODIUM - - METHOTREXATE TAB 2.5 MG - - MIRCERA SOLN PRSYR 100 MCG/0.3ML - - MIRCERA SOLN PRSYR 75 MCG/0.3ML - - MITOMYCIN RECON SOLN 20 MG - - MITOMYCIN RECON SOLN 5 MG - - MYCOPHENOLATE MOFETIL CAP 250 MG - - MYCOPHENOLIC ACID - - NEPHRAMINE - - ONCASPAR - - ONDANSETRON HCL 4 MG - - ONDANSETRON HCL 40 MG/20ML - - ONDANSETRON HCL SOLUTION 4 MG/2ML - FOLOTYN GAMMAGARD GAMMAGARD S/D LESS IGA GAMMAPLEX GENGRAF HEPATAMINE IDARUBICIN HCL IFEX INTRALIPID EMULSION 20 % IPRATROPIUM-ALBUTEROL IRINOTECAN HCL SOLUTION 40 MG/2ML JEVTANA LEVOLEUCOVORIN CALCIUM MESNA METHOTREXATE SODIUM (PF) METRONIDAZOLE IN NACL MIRCERA SOLN PRSYR 50 MCG/0.3ML MITOMYCIN 20 MG MITOMYCIN RECON SOLN 40 MG MUSTARGEN MYCOPHENOLATE MOFETIL TAB 500 MG NEBUPENT NULOJIX ONDANSETRON ONDANSETRON HCL 4 MG/2ML ONDANSETRON HCL 8 MG ONDANSETRON HCL SOLUTION 4 MG/5ML PAGE 37

38 - ONDANSETRON HCL SOLUTION 40 MG/20ML - ONDANSETRON HCL TAB 4 MG - OXALIPLATIN - PACLITAXEL CONC 30 MG/5ML - PARICALCITOL SOLUTION 2 MCG/ML - PROCALAMINE - PROSOL - RABAVERT - RECOMBIVAX HB - SANDIMMUNE CAP 100 MG - SANDIMMUNE SOLUTION 100 MG/ML - SIROLIMUS TAB 1 MG - TACROLIMUS CAP 0.5 MG - TACROLIMUS CAP 5 MG - TETANUS-DIPHTHERIA TOXOIDS TD - THYMOGLOBULIN - TOPOSAR - TORISEL - TREANDA RECON SOLN 100 MG - TREXALL - VENTAVIS - VINBLASTINE SULFATE SOLUTION 1 MG/ML - VINCASAR PFS - VORICONAZOLE RECON SOLN 200 MG - ZEMPLAR CAP 2 MCG - ONDANSETRON HCL TAB 24 MG - ONDANSETRON HCL TAB 8 MG - PACLITAXEL CONC 100 MG/16.7ML - PACLITAXEL CONC 300 MG/50ML - PREMASOL SOLUTION 6 % - PROGRAF SOLUTION 5 MG/ML - PULMOZYME - RAPAMUNE SOLUTION 1 MG/ML - RHEUMATREX - SANDIMMUNE CAP 25 MG - SIROLIMUS TAB 0.5 MG - SIROLIMUS TAB 2 MG - TACROLIMUS CAP 1 MG - TAXOTERE - THIOTEPA RECON SOLN 15 MG - TOBRAMYCIN NEBU SOLN 300 MG/5ML - TOPOTECAN HCL RECON SOLN 4 MG - TRAVASOL - TREANDA RECON SOLN 25 MG - UVADEX - VINBLASTINE SULFATE RECON SOLN 10 MG - VINCRISTINE SULFATE SOLUTION 1 MG/ML - VINORELBINE TARTRATE - ZEMPLAR CAP 1 MCG - ZINECARD - ZORTRESS PAGE 38

39 DETAILS This drug may be covered under Medicare Part B or D depending on the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination. PAGE 39

40 PRIFTIN PRIFTIN. 12/31/2015 PAGE 40

41 PROVIGIL - MODAFINIL TAB 100 MG - MODAFINIL TAB 200 MG Supporting statement of diagnosis from the physician 12/31/15 PAGE 41

42 QUININE QUININE SULFATE CAP 324 MG All FDA approved indications not otherwise excluded from Part D. Supporting statement of diagnosis and relevant medical information from physician 12/31/15 PAGE 42

43 REGRANEX REGRANEX Diabetic Neuropathic Ulcers: Diabetic patient with ulcer wound. Treatment will be given in combination with ulcer wound care (eg, debridement, infection control, and/or pressure relief). Diabetic Neuropathic Ulcers: Maximum 5 months. PAGE 43

44 RELISTOR - RELISTOR SOLUTION 12 MG/0.6ML - RELISTOR SOLUTION 8 MG/0.4ML. 12/31/2015 PAGE 44

45 REVATIO - REVATIO SOLUTION 10 MG/12.5ML - SILDENAFIL CITRATE TAB 20 MG Supporting statement of diagnosis from the physician 12/31/15 PAGE 45

46 REXULTI REXULTI All Medically Accepted Indications not otherwise excluded from Part D. Statement of Diagnosis from the prescriber and documented trial and failure, contraindication, or intolerance to aripiprazole. 12/31/2015 PAGE 46

47 SAMSCA SAMSCA Supporting statement of diagnosis from the physician 12/31/15 PAGE 47

48 SOVALDI SOVALDI Must have genotype 1,2,3,4,5, or 6 Patient must be age 18 or over. Prescriber must be a gastroenterologist, hepatologist, or infectious disease specialist 12 weeks:genotype 1,2,or4_24 wks:genotype 3 OR no interferon_48 wks:liver cancer awaiting transplant PAGE 48

49 STIVARGA STIVARGA Supporting statement of diagnosis from the physician 12/31/15 PAGE 49

50 XALKORI XALKORI Supporting statement of diagnosis from the physician that establishes the cancer as anaplastic lymphoma kinase (ALK)-positive must be prescribed by an oncologist 12/31/15 PAGE 50

51 XTANDI XTANDI Supporting statement of diagnosis from the physician and prior trial and failure of docetaxel 12/31/15 PAGE 51

52 ZOHYDRO ZOHYDRO ER All FDA approved indications not otherwise excluded from Part D. Must have severe pain requiring around the clock long term opioid, AND all of these: 1- ONE of the following formulary opioid options, hydrocodone IR, oxycodone IR, morphine IR, hydromorphone IR, methadone, OR oxymorphone IR are ineffective,not tolerated or inadequate for controlling pain AND fentanyl patches are ineffective, not tolerated, or inadequate for controlling pain 2-Must discontinue all other around-the-clock opioids when initiated 3-Care plan/agreement for opioid therapy has been established 4-Pt advised of risks and provides informed consent for chronic opioid therapy 5-Pt assessed for all these (i)pain severity (ii)suitability of non-opioids (iii)physical & emotional functional status (iv)risk of or current aberrant drug behavior 5-Prescriber will monitor for signs of misuse, abuse and addiction during therapy AND ONE of these: A-Opioid naive/non-tolerant must start at 10mg twice day for 7 days before titrating up OR B-Opioid tolerant, receiving one of these doses per day for at least 1 week: 60mg oral morphine, 25mcg transdermal fentanyl/hr, 30mg oral oxycodone, 8mg oral hydromorphone, 25mg oral oxymorphone Adults: 18 years and older. Prescriber is knowledgeable in the use of potent opioids for the management of chronic pain PAGE 52

53 90 days PAGE 53

BELEODAQ. Prior Authorization Criteria Memorial Hermann Advantage HMO & PPO Formulary ID: Version 10 Effective Date: 6/1/2015

BELEODAQ. Prior Authorization Criteria Memorial Hermann Advantage HMO & PPO Formulary ID: Version 10 Effective Date: 6/1/2015 Memorial Hermann Advantage HMO & PPO Formulary ID: 15190 Version 10 BELEODAQ BELEODAQ All FDA approved indications not otherwise excluded from Part D. Plan Year Y0110_PriorAuthCriteria4 IA 04/09/2015 PAGE

More information

COVERED USES All medically accepted indications not otherwise excluded from Part D

COVERED USES All medically accepted indications not otherwise excluded from Part D BOSULIF BOSULIF Signed statement of diagnosis from the physician, hepatic panel and CBC, trial and failure ofofimiatinib or dasatinibi and documentation of a 90 day response 12/31/15 PAGE 1 LAST UPDATED

More information

AgeWell 5 Tier 2016 Prior Authorization Criteria

AgeWell 5 Tier 2016 Prior Authorization Criteria ADCIRCA - ADCIRCA TAB 20MG. Patient requires nitrate therapy on a regular or intermittent basis Statement of diagnosis from the physician Effective 05/01/2016 1 BOSULIF - BOSULIF TAB 100MG BOSULIF TAB

More information

ANDROID. Products Affected ANDROID. Prior Authorization Criteria HEALTH CHOICE EXCHANGE Effective Date: 12/01/2016

ANDROID. Products Affected ANDROID. Prior Authorization Criteria HEALTH CHOICE EXCHANGE Effective Date: 12/01/2016 Prior Authorization HEALTH CHOICE EXCHANGE Effective Date: 12/01/2016 ANDROID ANDROID Supporting statement of diagnosis from the physician. Other 1 BLINCYTO BLINCYTO Known hypersensitivity to blinatumomab

More information

Agewell 1 Tier 2016 Prior Authorization Criteria

Agewell 1 Tier 2016 Prior Authorization Criteria ADCIRCA - ADCIRCA TAB 20MG. Patient requires nitrate therapy on a regular or intermittent basis Statement of diagnosis from the physician Effective 07/01/2016 1 BOSULIF - BOSULIF TAB 100MG BOSULIF TAB

More information

Drug Name Tier Drug Name Tier

Drug Name Tier Drug Name Tier Drug Name Tier Drug Name Tier ABELCET 100 MG/20 ML VIAL 4 ACETYLCYSTEINE 10% VIAL 2 ACETYLCYSTEINE 20% VIAL 2 ACYCLOVIR 1,000 MG/20 ML VIAL 2 ACYCLOVIR 500 MG/10 ML VIAL 2 ADRUCIL 500 MG/10 ML VIAL 2 ALBUTEROL

More information

Agewell 5 Tier 2016 Prior Authorization Criteria

Agewell 5 Tier 2016 Prior Authorization Criteria ADCIRCA - ADCIRCA TAB 20MG. Patient requires nitrate therapy on a regular or intermittent basis Statement of diagnosis from the physician 12/31/2016 Effective 11/01/2016 1 BOSULIF - BOSULIF TAB 100MG BOSULIF

More information

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D.

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D. ADCIRCA ADCIRCA. Other Patient requires nitrate therapy on a regular or intermittent basis Statement of diagnosis from the physician 12/31/2017 1 ALUNBRIG ALUNBRIG Other Diagnosis of metastatic, ALK positive

More information

ADCIRCA. Tribute 2017 Formulary 2017 Prior Authorization Criteria. Products Affected. Adcirca

ADCIRCA. Tribute 2017 Formulary 2017 Prior Authorization Criteria. Products Affected. Adcirca ADCIRCA Adcirca All FDA approved indications not otherwise excluded from Part D. Concomitant administration of riociguat with a specific PDE5 inhibitor (eg, sildenafil, tadalafil, vardenafil) Treatment

More information

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D.

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D. ADCIRCA ADCIRCA Other Concurrent use of organic nitrate or guanylate cyclase stimulators (includes intermittent use) Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic.

More information

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364 G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288

More information

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018 G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,

More information

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019 G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,

More information

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D.

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D. ADCIRCA ADCIRCA Age Concurrent use of organic nitrate or guanylate cyclase stimulators (includes intermittent use) Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic.

More information

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D.

ADCIRCA. Products Affected ADCIRCA. Covered Uses All medically accepted indications not otherwise excluded from Part D. ADCIRCA ADCIRCA Other Concurrent use of organic nitrate or guanylate cyclase stimulators (includes intermittent use) Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic.

More information

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion

More information

Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety

Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2015 PHYSICIAN QUALITY REPTING OPTIONS F INDIVIDUAL MEASURES REGISTRY ONLY DESCRIPTION:

More information

Did you know that some medications can be harmful to people 65 years or older?

Did you know that some medications can be harmful to people 65 years or older? Did you know that some medications can be harmful to people 65 years or older? What s the risk? Some medications can be dangerous to people 65 years of age or older. As we age, our bodies change. These

More information

ACAMPROSATE (CAMPRAL)

ACAMPROSATE (CAMPRAL) ACAMPROSATE (CAMPRAL) ACAMPROSATE CALCIUM Creatinine clearance less than 30 PAGE 1 LAST UPDATED 06/2016 ADALIMUMAB (HUMIRA) HUMIRA, HUMIRA PEDIATRIC CROHN'S, HUMIRA PEN, HUMIRA PEN CROHN'S-UC-HS, HUMIRA

More information

2014 FORMULARY CHANGE NOTICE PLEASE NOTE THESE IMPORTANT CHANGES TO YOUR 2014 FORMULARY (LIST OF COVERED DRUGS)

2014 FORMULARY CHANGE NOTICE PLEASE NOTE THESE IMPORTANT CHANGES TO YOUR 2014 FORMULARY (LIST OF COVERED DRUGS) Cigna Medicare Rx Secure-Xtra (PDP) 2014 FORMULARY CHANGE NOTICE PLEASE NOTE THESE IMPORTANT CHANGES TO YOUR 2014 FORMULARY (LIST OF COVERED DRUGS) Effective date of : 03/01/2014 ASACOL 400MG TABLET deletion

More information

To help doctors give their patients the best possible care, the American

To help doctors give their patients the best possible care, the American Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific

More information

2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements

2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements 2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) with Prior Authorization Requirements You may need prior authorization for certain drugs that are on the formulary or drugs

More information

Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety

Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2016 PHYSICIAN QUALITY REPORTING OPTIONS FOR INDIVIDUAL MEASURES REGISTRY ONLY DESCRIPTION:

More information

Advantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011

Advantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011 Advantage by Peach State Health Plan 2012 Approved 10/23/2011 Effective October 2011 Note to members: The prior authorization requirements are listed to provide you with information to discuss treatment

More information

Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety

Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:

More information

MDwise Self-Administered Codes for Medical

MDwise Self-Administered Codes for Medical The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively

More information

2010 Drugs Requiring Prior Authorization

2010 Drugs Requiring Prior Authorization 2010 Drugs Requiring Prior Authorization Drugs Covered Uses Exclusion Criteria Actemra (tocilizumab) Adcirca (tadalafil) Alfa Interferons - Alferon N - Infergen - PEG-Intron - PEG-Intron Redipen - Pegasys

More information

TennCare Program TN MAC Price Change List As of: 03/30/2017

TennCare Program TN MAC Price Change List As of: 03/30/2017 1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017

More information

Partners Notice of Change March 2017

Partners Notice of Change March 2017 New Added Products: Effective 3/1/2017 Drug Reason Tier Restrictions abacavir 600 mg-lamivudine 300 QL ADRENACLICK 0.15 MG/0.15 ML INJECTION,AUTO- INJECTOR ADRENACLICK 0.3 MG/0.3 ML INJECTION, AUTO- INJECTOR

More information

Quality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety

Quality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety Quality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:

More information

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1 drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A

More information

Specialty Drug List - Sorted by Therapeutic Class Developed for the Mississippi Division of Medicaid by Mercer

Specialty Drug List - Sorted by Therapeutic Class Developed for the Mississippi Division of Medicaid by Mercer ANTI-INFECTIVE ABELCET 100 MG/20 ML VIAL 4/1/2017 ANTI-INFECTIVE AMBISOME 50 MG VIAL 4/1/2017 ANTI-INFECTIVE ANCOBON 250 MG CAPSULE 4/1/2017 ANTI-INFECTIVE ANCOBON 500 MG CAPSULE 4/1/2017 ANTI-INFECTIVE

More information

Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A

More information

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine

More information

PEGINTRON (peginterferon alfa-2b) SECTION 1: Pegintron - Hepatitis C Monotherapy

PEGINTRON (peginterferon alfa-2b) SECTION 1: Pegintron - Hepatitis C Monotherapy SECTION 1: Hepatitis C Pegintron SECTION 2: Hepatitis C Pegintron & Ribavirin SECTION 3: Hepatitis C Pegintron, Ribavirin, & Sovaldi SECTION 4: Hepatitis C Pegintron, Ribavirin, & Olysio SECTION 1: Pegintron

More information

UP Health System Marquette Medication Guideline High Alert Drugs

UP Health System Marquette Medication Guideline High Alert Drugs 1 ALTEPLASE SOLR 100 MG ACTIVASE 305010 50242008527 TRUE ALTEPLASE SOLR 50 MG ACTIVASE 305008 50242004413 TRUE AMIODARONE INJ 50 MG/ML CORDARONE IV 305035 63323061609 TRUE AMIODARONE INJ 50 MG/ML CORDARONE

More information

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017 ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE

More information

RIVERSPRING STAR ISNP PRIOR AUTHORIZATION

RIVERSPRING STAR ISNP PRIOR AUTHORIZATION ACROMEGALY RIVERSPRING STAR ISNP PRIOR AUTHORIZATION SIGNIFOR, SIGNIFOR LAR, SOMATULINE DEPOT, SOMAVERT 10 MG VIAL, SOMAVERT 15 MG VIAL, SOMAVERT 20 MG VIAL Must provide clinical documentation of Acromegaly

More information

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN ACTIMMUNE CARE N CARE HEALTH PLAN Actimmune Age 1 ADAGEN Adagen Age Severe thrombocytopenia. Use in preparation for or in support of bone marrow transplantation. Use for direct replacement for deficient

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Prior Authorization Guideline

Prior Authorization Guideline Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Riesbeck's Pharmacy Reward Club Generic Medication List February 2018 $4 30 Day Supply

Riesbeck's Pharmacy Reward Club Generic Medication List February 2018 $4 30 Day Supply Allergy, Cold & Flu Antibiotic Treatments Arthritis & Pain Benzonatate 100mg cap 14 42 Diphenhydramine HCl Cap 50 MG 30 90 Diphenhydramine HCl Inj 50MG/ML 1 3 Diphenhydramine HCl Liquid 12.5 MG/5ML 720ml

More information

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018 ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA

More information

Alprazolam 0.25mg, 0.5mg, 1mg tablets

Alprazolam 0.25mg, 0.5mg, 1mg tablets Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service

More information

Provider Toolkit PFFS/PPO

Provider Toolkit PFFS/PPO Provider Toolkit 2014 2015 Y0067_PR_PhysTlkt_0514_IA 05/14/2014 PFFS/PPO TABLE OF CONTENTS Sample Letter from Physician to Patient...4 HEDIS Quick Reference Guide...5 High Risk Medication Formulary Alternative

More information

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).

Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl

More information

Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum

Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum Below is a list formulary changes for the benefit year 2018. This is not a complete list of drugs covered by the Part D plan. The

More information

Aetna Better Health Illinois Premier Plan. November 2015 Formulary Updates. October 2015 Formulary Updates

Aetna Better Health Illinois Premier Plan. November 2015 Formulary Updates. October 2015 Formulary Updates Aetna Better Health Illinois Premier Plan November 2015 Formulary Updates desogestrel & ethinyl estradiol tab 0.15 mg-30 mcg RIVASTIGMINE DIS 13.3/24; QL (30 patches/30 days) RIVASTIGMINE DIS 4.6MG/24;

More information

2016 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements

2016 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements 2016 AlohaCare Advantage Plus Formulary (HMO SNP) with Prior Authorization Requirements You may need prior authorization for certain drugs that are on the formulary or drugs that are not on the formulary.

More information

Plan Year 2019 Prior Authorization (PA) Criteria

Plan Year 2019 Prior Authorization (PA) Criteria Plan Year 2019 Prior Authorization (PA) Criteria Prior Authorization: Commonwealth Care Alliance requires you (or your physician) to get prior authorization for certain drugs. This means that you will

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Morphine Sulfate Hydromorphone Oxymorphone

Morphine Sulfate Hydromorphone Oxymorphone Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone

More information

Fruth Pharmacy Prescription Savings Club Prescription Club October 2010 Generics item list 30 Day Qty

Fruth Pharmacy Prescription Savings Club Prescription Club October 2010 Generics item list 30 Day Qty Fruth Pharmacy Prescription Savings Club Prescription Club October 2010 Generics item list Antihistamine Drugs Cyproheptadine HCl Tab 4 mg Anti-Infective Agents Diphenhydramine HCl Cap mg Promethazine

More information

DRUG EXTRAVASATION. Vesicants. Irritants

DRUG EXTRAVASATION. Vesicants. Irritants DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)

More information

Medicare Part B Covered Medications

Medicare Part B Covered Medications This table provides a reference guide for the most frequent Part B/D coverage determination scenarios facing Part D plans and Part D pharmacy providers. It does not address all potential situations. For

More information

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)

Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta

More information

Riesbeck's Pharmacy Reward Club Generic Medication List October 2017

Riesbeck's Pharmacy Reward Club Generic Medication List October 2017 Allergy, Cold & Flu Antibiotic Treatments Arthritis & Pain Benzonatate 100mg cap 14 42 Diphenhydramine HCl Cap 50 MG 30 90 Diphenhydramine HCl Inj 50MG/ML 1 3 Diphenhydramine HCl Liquid 12.5 MG/5ML 720ml

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

TN Cover Rx Tennessee CoverRx MAC Price Change List As of: 04/26/2018

TN Cover Rx Tennessee CoverRx MAC Price Change List As of: 04/26/2018 1 Tennessee CoverRx List Run : 04/26/18 Dosage Form amiodarone HCl 200 MG TABLET ORAL 04/25/2018 0.16102 0.14405 11.8 hydralazine HCl 100 MG TABLET ORAL 04/25/2015 0.11390 0.10854 4.9 hydralazine HCl 25

More information

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: Palonosetron Hydrochloride (Aloxi ) 09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Riesbeck's Pharmacy Reward Club Generic Medication List September 2017

Riesbeck's Pharmacy Reward Club Generic Medication List September 2017 Drug Category Allergy, Cold & Flu Antibiotic Treatments Arthritis & Pain Riesbeck's Benzonatate 100mg cap 14 42 Diphenhydramine HCl Cap 50 MG 30 90 Diphenhydramine HCl Liquid 12.5 MG/5ML 720ml 2160ml Hydroxyzine

More information

Nebraska Medicaid Program NE Weekly MAC Price Change List For Period: 12/14/ /20/2017

Nebraska Medicaid Program NE Weekly MAC Price Change List For Period: 12/14/ /20/2017 1 Medicaid Run : 12/21/17 NE Weekly List Old AMIODARONE HCL 200 MG TABLET ORAL 12/20/2017 0.15321 0.14370 6.6 HYDRALAZINE HCL 10 MG TABLET ORAL 12/20/2017 0.05226 0.05213 0.2 LISINOPRIL 10 MG TABLET ORAL

More information

New Product to Market: Lonhala Magnair

New Product to Market: Lonhala Magnair Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the May 17, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.

More information

Buckeye Health Plan (MMP) 2016 Prior Authorization Criteria

Buckeye Health Plan (MMP) 2016 Prior Authorization Criteria Buckeye Health Plan (MMP) 2016 Prior Authorization Instructions: 1. With this file, at the top, click Edit, then click Find. 2. In the Find box type the name of the medication you want to find. 3. Click

More information

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication

More information

Duragesic patch. Duragesic patch (fentanyl patch) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl

More information

Products Affected ACTEMRA SUBCUTANEOUS ACTEMRA INTRAVENOUS SOLUTION 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML)

Products Affected ACTEMRA SUBCUTANEOUS ACTEMRA INTRAVENOUS SOLUTION 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) Current as of October 1, 2016 ACTEMRA ACTEMRA SUBCUTANEOUS ACTEMRA INTRAVENOUS SOLUTION 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) PA Other Documentation of diagnosis, previous treatment with one or

More information

MASCC Guidelines for Antiemetic control: An update

MASCC Guidelines for Antiemetic control: An update MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,

More information

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations Kentucky Department for Medicaid Services Pharmacy and May 17, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,

More information

Professionalism & Service with Great Prices

Professionalism & Service with Great Prices Acyclovir Capsules 200mg Viruses 30 90 Albuterol Syrup 2mg/5ml Asthma 120 360 Albuterol Sulfate Solution 0.05% * Asthma ----- ----- 20 60 Albuterol Sulfate Solution 0.083% Asthma ----- ----- 75 225 Alendronate

More information

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black

More information

2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased

2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 5 Last Review Date: June 24, 2016 Gilotrif Description Gilotrif (afatinib)

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

The following are J Code requirements

The following are J Code requirements The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based

More information

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) 09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT

More information

Prior Authorization Criteria ACTIMMUNE

Prior Authorization Criteria ACTIMMUNE Prior Authorization ACTIMMUNE ACTIMMUNE Covered Uses All FDA-approved indications not otherwise excluded from Part D. Age Effective 01/01/2019 Page 1 of 150 ADEMPAS Prior Authorization ADEMPAS Covered

More information

Technivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description

Technivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Technivie Page: 1 of 6 Last Review Date: March 18, 2016 Technivie Description Technivie (ombitasvir,

More information

Zepatier. Zepatier (elbasvir, grazoprevir) and Ribavirin. Description

Zepatier. Zepatier (elbasvir, grazoprevir) and Ribavirin. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Zepatier Page: 1 of 6 Last Review Date: March 18, 2016 Zepatier Description Zepatier (elbasvir,

More information

Pharmacy Savings Program

Pharmacy Savings Program Pharmacy Savings Program SELECT GENERICS DRUG LIST The Pharmacy Savings Program provides you with savings on select generic medications included on this list. The prices for these select generic medications

More information

WELLCARE/ OHANA HEALTH PLAN

WELLCARE/ OHANA HEALTH PLAN WELLCARE/ OHANA HEALTH PLAN 2014 PRIOR AUTHORIZATION CRITERIA No Changes Made Since: 08/2014 **To get updated information about the drugs covered by WellCare, please visit our website (https://www.wellcare.com)

More information

Oral Cystic Fibrosis Modulators

Oral Cystic Fibrosis Modulators Oral Cystic Fibrosis Modulators Goals: To ensure appropriate drug use and limit to patient populations in which they have demonstrated to be effective and safe. To monitor for clinical response for appropriate

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)

More information

2014 Quantity Limits (QL) Criteria

2014 Quantity Limits (QL) Criteria 2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food

More information

Ally Rx D-SNP Current as of r 1, 2017

Ally Rx D-SNP Current as of r 1, 2017 Ally Rx D-SNP Current as of r 1, 2017 AMPYRA AMPYRA PA Moderate to severe renal impairment (CrCL less than or equal to 50ml/min), patient not able to walk 25 feet in 8-45 seconds. Documentation of diagnosis,

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last

More information

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111

MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335

More information

Plan Year 2017 Prior Authorization (PA) Criteria

Plan Year 2017 Prior Authorization (PA) Criteria Plan Year 2017 Prior Authorization (PA) Criteria Prior Authorization: Commonwealth Care Alliance requires you (or your physician) to get prior authorization for certain drugs. This means that you will

More information

CARE N CARE HEALTH PLAN

CARE N CARE HEALTH PLAN ACTIMMUNE ACTIMMUNE Covered Uses All FDA-approved indications not otherwise excluded from Part D. Other 1 ADEMPAS ADEMPAS Covered Uses All medically accepted indications not otherwise excluded from Part

More information

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV 09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,

More information

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda

More information

Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin

More information